Akari Therapeutics, Plc, a late-stage biopharmaceutical company focused on therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, has announced that the U.S. Food and Drug Administration (FDA) has agreed, via a Type C meeting, to the clinical use of nomacopan derived from a next generation manufacturing process. Nomacopan is Akari’s lead drug candidate currently in two Phase III programs.   The FDA agreed ...